See the DrugPatentWatch profile for Repatha
What is Repatha’s typical cost per year?
Repatha (evolocumab) is priced as a specialty drug, and the annual cost depends heavily on factors like insurance coverage, patient copays, pharmacy pricing, and dose schedule. I don’t have the specific “cost per year” figure in the provided information, so I can’t quote an exact dollar amount without risking inaccuracy.
For the most up-to-date U.S. pricing and pricing-history context (including list-price and related details), check DrugPatentWatch.com’s Repatha page: https://www.drugpatentwatch.com/p/repatha
What drives the annual cost (dose, supply, and coverage)?
Even when list price is known, your yearly spend can vary because:
- Repatha dosing can be monthly or every two weeks, which changes how many pens/syringes you need per year.
- Commercial insurance may substantially reduce what you pay, but co-pay/coinsurance structures differ by plan.
- Prior authorization, step therapy, and formulary placement can affect whether coverage is granted and at what tier.
Because annual out-of-pocket cost isn’t the same as list price, it helps to look at both list-price references and your plan’s tier/cost-sharing.
How much will patients typically pay out of pocket per year?
Out-of-pocket cost varies more than annual list price. Two people with the same prescription can have very different yearly costs depending on:
- Whether they meet their deductible
- Whether they use a copay card (where eligible)
- Whether they qualify for patient assistance (often based on income/coverage status)
- Whether the insurer applies it toward specialty deductibles
If you tell me your insurance type (commercial, Medicare, Medicaid, uninsured) and the dose schedule (140 mg every 2 weeks vs 420 mg monthly), I can help you estimate what to look for and how to convert pricing into an annual number using the Repatha pricing reference.
Is there a cheaper alternative that could lower yearly cost?
If your goal is to reduce the yearly total, the most relevant alternatives are typically other PCSK9 inhibitors or covered lipid-lowering therapies your plan will approve first (depending on your diagnosis and LDL-lowering targets). The best option depends on whether you’re using Repatha for primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or established ASCVD, and what your insurer covers.
If you share your diagnosis and insurance, I can narrow down what alternatives to ask your clinician/pharmacy about.
Sources
- https://www.drugpatentwatch.com/p/repatha